J 2023

Analysis of rare driving events in pediatric acute myeloid leukemia

NOORT, Sanne, van Oosterwijk JOLIEKE, Jing MA, Elizabeth A R GARFINKLE, Stephanie NANCE et. al.

Basic information

Original name

Analysis of rare driving events in pediatric acute myeloid leukemia

Authors

NOORT, Sanne, van Oosterwijk JOLIEKE, Jing MA, Elizabeth A R GARFINKLE, Stephanie NANCE, Michael WALSH, Guangchun SONG, Dirk REINHARDT, Martina PIGAZZI, Franco LOCATELLI, Henrik HASLE, Jonas ABRAHAMSSON, Marie JAROŠOVÁ (203 Czech Republic, belonging to the institution), Charikleia KELAIDI, Sophia POLYCHRONOPOULOU, Marry M VAN DEN HEUVEL-EIBRINK, Maarten FORNEROD, Tanja A GRUBER and C Michel ZWAAN (guarantor)

Edition

haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2023, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 10.100 in 2022

RIV identification code

RIV/00216224:14110/23:00131006

Organization unit

Faculty of Medicine

UT WoS

001000812400004

Keywords in English

pediatric acute myeloid leukemia; rare driving events

Tags

Tags

International impact, Reviewed
Změněno: 21/6/2023 08:20, Mgr. Tereza Miškechová

Abstract

V originále

Elucidating genetic aberrations in pediatric acute myeloid leukemia (AML) provides insight in biology and may impact on risk-group stratification and clinical outcome. This study aimed to detect such aberrations in a selected series of samples without known (cyto)genetic aberration using molecular profiling. A cohort of 161 patients was selected from various study groups: DCOG, BFM, SJCRH, NOPHO and AEIOP. Samples were analyzed using RNA sequencing (n=152), whole exome (n=135) and/or whole genome sequencing (n=100). In 70 of 156 patients (45%), of whom RNA sequencing or whole genome sequencing was available, rearrangements were detected, 22 of which were novel; five involving ERG rearrangements and four NPM1 rearrangements. ERG rearrangements showed self-renewal capacity in vitro, and a distinct gene expression pattern. Gene set enrichment analysis of this cluster showed upregulation of gene sets derived from Ewing sarcoma, which was confirmed comparing gene expression profiles of AML and Ewing sarcoma. Furthermore, NPM1-rearranged cases showed cytoplasmic NPM1 localization and revealed HOXA/B gene overexpression, as described for NPM1 mutated cases. Single-gene mutations as identified in adult AML were rare. Patients had a median of 24 coding mutations (range, 7-159). Novel recurrent mutations were detected in UBTF (n=10), a regulator of RNA transcription. In 75% of patients an aberration with a prognostic impact could be detected. Therefore, we suggest these techniques need to become standard of care in diagnostics.